This is an observational, retrospective, UK \& Ireland audit measuring patient adherence to Rebif® injections with the RebiSmart™ injection device. Data will be collected from Multiple Sclerosis (MS) patients who have been prescribed Rebif® and have been using the RebiSmart™ device for injection for a minimum of 24 months.
Study Type
OBSERVATIONAL
Enrollment
230
Please contact the
Merck KGaA Communication Center For Recruiting Locations, United Kingdom
Patient Adherence
Percentage "RebiSmart measured" patient adherence to Rebif® injections
Time frame: 24 months
Patient Adherence
Percentage "RebiSmart measured" patient adherence to Rebif® injections
Time frame: 1 month
Patient Adherence
Percentage "RebiSmart™ measured" patient adherence to Rebif® injections
Time frame: 3 months
Patient Adherence
Percentage "RebiSmart™ measured" patient adherence to Rebif® injections
Time frame: 6 months
Patient Adherence
Percentage "RebiSmart™ measured" patient adherence to Rebif® injections
Time frame: 12 months
Difference in patient adherence over time
Difference in percentage patient adherence between the first 12 months and second 12 months of treatment period.
Time frame: 12 months
Medication Possession Ratio
Difference of the patient MPR (as a percentage) versus the patient's RebiSmart™ recorded percentage adherence levels
Time frame: 12 months
Medication Possession Ratio
Difference of the patient MPR (as a percentage) versus the patient's RebiSmart™ recorded percentage adherence levels
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adherence of patient subgroups
"RebiSmart™ measured" percentage adherence within and between the following patient sub-groups: * patients who are and are not registered to MySupport (Rebif Support Programme) * patient age groups * patient gender * prior use of a DMT
Time frame: 12 months
Adherence of patient subgroups
"RebiSmart™ measured" percentage adherence within and between the following patient sub-groups: * patients who are and are not registered to MySupport (Rebif Support Programme) * patient age groups * patient gender * prior use of a DMT
Time frame: 24 months
Patient Adherence in the UK versus Ireland
Reporting of UK and Ireland actual adherence levels separately
Time frame: 12 months
Patient Adherence in the UK versus Ireland
Reporting of UK and Ireland actual adherence levels separately
Time frame: 24 months
Device Comfort Settings
Preferred final comfort settings (at last injection)
Time frame: 12 months